News >

Venetoclax Triplet Shows Promise in Relapsed/Refractory Multiple Myeloma

Jason Harris
Published: Friday, Aug 31, 2018

Luciano Costa, MD, PhD

Luciano Costa, MD, PhD
The combination of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone may provide a new treatment option for patients with relapsed/refractory multiple myeloma, according to Luciano J. Costa, MD, PhD.

, Costa discussed the emerging potential of combing venetoclax with carfilzomib and dexamethasone as a treatment for patients with relapsed/refractory multiple myeloma.

OncLive: Can you provide an overview of the phase II triplet study?

Costa: We presented phase II results of a combination of venetoclax, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. This study was done across multiple institutions in the United States. We accrued 42 patients, and we presented safety data on those 42 patients and efficacy data on a subset of 30 patients who were enrolled 3 or more months prior to the data cutoff.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x